Phenotypic and genotypic analysis of clarithromycin-resistant Helicobacter pylori from Bogotá D.C., Colombia

Journal of Microbiology

Volumn 51, Issue 4, 2013, Pages 448-452

  Trespalacios, Alba A ^a   Otero, William ^b,e   Caminos, Jorge E ^c   Mercado, Marcela M ^a   Ávila, Jenny ^a   Rosero, Liliana E ^a   Arévalo, Azucena ^a   Poutou Piñales, Raúl A ^c   Graham, David Y ^a,d  

^a PONTIFICIA UNIVERSIDAD JAVERIANA   (Colombia)

^b Unidad de Gastroenterología Clínica Fundadores   (Colombia)

^c UNIVERSIDAD NACIONAL DE COLOMBIA   (Colombia)

^d MICHAEL E DEBAKEY VETERANS AFFAIRS MEDICAL CENTER   (United States)

^e BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

23S rRNA mutations; clarithromycin resistance; Helicobacter pylori

Indexed keywords

ANTIINFECTIVE AGENT; CLARITHROMYCIN; RNA 23S;

ADULT; AGED; ANTIBIOTIC RESISTANCE; ARTICLE; COLOMBIA; DRUG EFFECT; GENETICS; GENOTYPE; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMAN; ISOLATION AND PURIFICATION; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; MIDDLE AGED; MUTATION; NUCLEOTIDE SEQUENCE; PHENOTYPE; YOUNG ADULT;

ADULT; AGED; ANTI-BACTERIAL AGENTS; CLARITHROMYCIN; COLOMBIA; DNA MUTATIONAL ANALYSIS; DRUG RESISTANCE, BACTERIAL; GENOTYPE; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; MUTATION; PHENOTYPE; RNA, RIBOSOMAL, 23S; YOUNG ADULT;

EID: 84883395920     PISSN: 12258873     EISSN: 19763794     Source Type: Journal    
DOI: 10.1007/s12275-013-2465-6     Document Type: Article

References (37)

1. Agudo, S., Perez-Perez, G., Alarcón, T., and López-Brea, M. 2010. High prevalence of clarithromycin-resistant Helicobacter pylori strains and risk factors associated with resistance in Madrid, Spain. J. Clin. Microbiol. 48, 3703-3707.
2. Alarcón, T., Domingo, D., Prieto, N., and López-Brea, M. 2000. Clarithromycin resistance stability in Helicobacter pylori: influence of the MIC and type of mutation in the 23S rRNA. J. Antimicrob. Chemother. 46, 613-616.
3. Alarcón, T., Domingo, D., Prieto, N., de la Obra, P., and López-Brea, M. 2002. Actividad in vitro de claritromicina y metronidazol frente a Helicobacter pylori en diferentes atmósferas de incubación. Rev. Españala de Quimioterapia. 15, 341-345.
4. Álvarez, A., Moncayo, J. I., Santacruz, J. J., Corredor, L. F., Reinosa, E., Martínez, J. W., and Beltrán, L. 2009a. Resistencia a metronidazol y claritromicina en aislamientos de Helicobacter pylori de pacientes dispépticos en Colombia. Rev. Méd. Chile137, 1309-1314.
5. Álvarez, A., Moncayo, J. I., Santacruz, J. J., Santacoloma, M., Corredor, L. F., and Reinosa, E. 2009b. Antimicrobial susceptibility and mutations involved in clarithromycin resistance in Helicobacter pylori isolates from patients in the western central region of Colombia. Antimicrob. Agent Chemother. 53, 4022-4024.
6. Ansorg, R., Von Recklinghausen, G., Pomarius, R., and Schmid, E. N. 1991. Evaluation of techniques for isolation, subcultivation, and preservation of Helicobacter pylori. J. Clin. Microbiol. 29, 51-53.
7. Arévalo-Galvis, A., Trespalacios-Rangel, A. A., Otero, W., Mercado-Reyes, M., and Poutou-Piñales, R. A. 2012. PPrevalence of cagA, vacA, babA2 and iceA genes in H. pylori strains isolated from Colombian patients with functional dyspepsia. Pol. J. Microbiol. 61, 33-40.
8. Barile, K. A., Silva, A. L., Xavier, J. N., Assumpção, M. B., and Corvelo, T. C. 2010. Characterization of 23S rRNA domain V mutations in gastric biopsy patients from the eastern Amazon. Mem. Inst. Oswaldo Cruz. 105, 314-317.
9. Clinical and Laboratory Standards Institute. 2010. Performance standards for antimicrobial susceptibility testing; Twentieth informational supplement. M100-S20.
10. Correa, P., van Doorn, L.-J., Bravo, J. C., Ruiz, B., Bravo, L. E., and Realpe, J. L. 2000. Unsuccessful treatment results in survival of less virulent genotypes of Helicobacter pylori in Colombian patients. Am. J. Gastroenterol. 95, 564-566.
11. De Francesco, V., Giorgio, F., Hassan, C., Manes, G., Vannella, L., Panella, C., Ierardi, E., and Zullo, A. 2010a. Worldwide H. pylori antibiotic resistance: A systematic review J. Gastrointestin. Liver Dis. 19, 409-414.
12. 13C]urea breath test values. J. Med. Microbiol. 59, 588-591.
13. De Francesco, V., Zullo, A., Ierardi, E., Giorgio, F., Perna, F., Hassan, C., Morini, S., Panella, C., and Vaira, D. 2010c. Phenotypic and genotypic Helicobacter pylori clarithromycin resistance and therapeutic outcome: benefits and limits. J. Antimicrob. Chemother. 65, 327-332.
14. Duque-Jamaica, R., Arévalo-Galvis, A., Poutou-Piñales, R. A., and Trespalacios-Rangel, A. A. 2010. Sequential statistical improvement of the liquid cultivation of Helicobacter pylori. Helicobacter15, 303-312.
15. Fontana, C., Favaro, M., Minelli, S., Criscuolo, A. A., Pietroiusti, A., Galante, A., and Favalli, C. 2002. New site of modification of 23S rRNA associated with clarithromycin resistance of Helicobacter pylori clinical isolates. Antimicrob. Agent Chemother. 46, 3765-3769.
16. Graham, D. Y., Lu, H., and Yamaoka, Y. 2008. Therapy for Helicobacter pylori infection can be improved. Drugs68, 725-736.
17. Graham, D. Y., Malaty, H. M., Evans, D. G., Evans, D. J., Klein, P. D., and Adam, E. 1991. Epidemiology of Helicobacter pylori in an asymptomatic population in the United States. Effect of age, race, and socioeconomic status. Gastroenterol. 100, 1495-1501.
18. Henao, S. C., Quiroga, A., Martínez, J. D., and Otero, W. 2009. Resistencia primaria a la claritromicina en aislamientos de Helicobacter pylori. Rev. Col. Gastroenterol. 24, 110-114.
19. Hirata, K., Suzuki, H., Nishizawa, T., Tsugawa, H., Muraoka, H., Saito, Y., Matsuzaki, J., and Hibi, T. 2010. Contribution of efflux pumps to clarithromycin resistance in Helicobacter pylori. J. Gastroenterol. Hepatol. 25, Suppl 1, S75-S79.
20. Kato, S., Fujimura, S., Udagawa, H., Shimizu, T., Maisawa, S., Ozawa, K., and Iinuma, K. 2002. Antibiotic resistance of Helicobacter pylori strains in Japanese children. J. Clin. Microbiol. 40, 649-653.
21. Kato, M., Yamaoka, Y., Kim, J. J., Reddy, R., Asaka, M., Kashima, K., Osato, M. S., El-Zaatari, F. A. K., Graham, D. Y., and Kwon, D. H. 2000. Regional differences in metronidazole resistance and increasing clarithromycin resistance among Helicobacter pylori isolates from Japan. Antimicrob. Agent Chemother. 44, 2214-2216.
22. Kim, K. S., Kang, J. O., Eun, C. S., Han, D. S., and Choi, T. Y. 2002. Mutations in the 23S rRNA gene of Helicobacter pylori associated with clarithromycin resistance. J. Korean Med. Sci. 17, 599-603.
23. Liu, Z., Zheng, P., and Yang, P. 2008. Efflux pump gene hefA of Helicobacter pylori plays an important role in multidrug resistance. World J. Gastroenterol. 14, 5217-5222.
24. Maeda, S., Yoshida, H., Matsunaga, H., Ogura, K., Kawamata, O., Shiratori, Y., and Omata, M. 2000. Detection of clarithromycin-resistant Helicobacter pylori strains by a preferential homoduplex formation assay. J. Clin. Microbiol. 38, 210-214.
25. Malfertheiner, P., Megraud, F., O'Morain, C., Bazzoli, F., El-Omar, E., Graham, D., Hunt, R., Rokkas, T., Vakil, N., and Kuipers, E. J. 2007. Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report. Gut56, 772-781.
26. Marais, A., Monteiro, L., Occhialini, A., Pina, M., Lamouliatte, H., and Mégraud, F. 1999. Direct detection of Helicobacter pylori resistance to macrolides by a polymerase chain reaction/DNA enzyme immunoassay in gastric biopsy specimens. Gut44, 463-467.
27. Pan, Z. J., Su, W. W., Tytgat, G. N. J., Dankert, H., and Ende, A. 2002. Assessment of clarithromycin-resistant Helicobacter pylori among patients in Shanghai and Guangzhou, China, by primer-mismatch PCR. J. Clin. Microbiol. 40, 259-261.
28. Rimbara, E., Fischbach, L. A., and Graham, D. Y. 2011. Optimal therapy for Helicobacter pylori infections. Nat. Rev. 8, 79-88.
29. Rimbara, E., Noguchi, N., Kawai, T., and Sasatsu, M. 2008. Novel mutation in 23S rRNA that confers low-level resistance to clarithromycin in Helicobacter pylori. Antimicrob. Agent Chemother. 52, 3465-3466.
30. Stone, G. G., Shortridge, D., Versalovic, J., Beyer, J., Flamn, R. K., Graham, D. Y., Ghoneim, A. T., and Tanaka, S. K. 1997. PCR oligonucleotide ligation assay to determine the prevalence of 23S rRNA gene mutations in clarithromycin-resistant Helicobacter pylori. Antimicrob. Agent Chemother. 41, 712-714.
31. Taylor, D. E., Ge, Z., Purych, D., Lo, T., and Hiratsuka, K. 1997. Cloning and sequence analysis of two copies of a 23S rRNA gene from Helicobacter pylori and association of clarithromycin resistance with 23S rRNA mutations. Antimicrob. Agent Chemother. 41, 2621-2628.
32. Trespalacios, A. A., Otero Regino, W., and Mercado Reyes, M. 2010. Resistencia de Helicobacter pylori a metronidazol, claritromicina y amoxicilina en pacientes colombianos. Rev. Col. Gastroenterol. 25, 31-38.
33. Vakil, N. and Megraud, F. 2007. Eradication therapy for Helicobacter pylori. Gastroenterol. 133, 985-1001.
34. Vallejos, M. C., Garrido, O. L., Cáceres, L. D., Madrid, A. M., Defilippi, C., Defilippi, C. C., and Toledo, A. H. 2007. Prevalencia de la resistencia a metronidazol, claritromicina y tetraciclina en Helicobacter pylori aislado de pacientes de la Región Metropolitana. Rev. Méd. Chile135, 287-293.
35. van Doorn, L. J., Glupczynski, Y., Kusters, J. G., Megraud, F., Midolo, P., Maggi-Solca, N., Queiroz, D. M. M., Nouhan, N., Stet, E., and Quint, W. G. V. 2001. Accurate prediction of macrolide resistance in Helicobacter pylori by a PCR line probe assay for detection of mutations in the 23S rRNA gene: multicenter validation study. Antimicrob. Agent Chemother. 45, 1500-1504.
36. Versalovic, J., Osato, M. S., Spakovsky, K., Dore, M. P., Reddy, R., Stone, G. G., Shortridge, D., Flamm, R. K., Tanaka, S. K., and Graham, D. Y. 1997. Point mutations in the 23S rRNA gene of Helicobacter pylori associated with different levels of clarithromycin resistance. J. Antimicrob. Chemother. 40, 283-286.
37. Yamaoka, Y., Kodama, T., Kita, M., Imanishi, J., Kashima, K., and Graham, D. Y. 1999. Relation between clinical presentation, Helicobacter pylori density, interleukin 1 and 8 production, and cagA status. Gut45, 804-811.